 NEW YORK and VIENNA, Austria, June 07, 2021 GLOBE NEWSWIRE -- HOOKIPA Pharma Inc. NASDAQ: HOOK, HOOKIPA, a company developing a new class of immunotherapeutics based on its proprietary arenavirus platform, today reported positive Phase 1 data from its ongoing Phase 12 study NCT04180215 of HB-200 for the treatment of advanced Human Papillomavirus 16-positive HPV16 cancers. Data presented as an oral presentation abstract 2502 at the 2021 American Society of Clinical Oncology ASCO Annual Meeting showed outstanding T cell responses, preliminary efficacy as a monotherapy in heavily pretreated patients who progressed on standard of care, including checkpoint inhibitors, and favorable tolerability. The company also announced translational data suggesting a relationship between T cell response and potential clinical efficacy. The company will host an investor event today at 6:30pm EDT. 